Therefore, the down-regulation of PVN Gαq proteins plays a critical counter-regulatory role in preventing AVP hypersecretion by reducing the ability of endogenous GPCR ligands to trigger AVP release, and may represent a new therapeutic target in pathophysiological states featuring AVP dysregulation (e.g., heart failure, salt-sensitive hypertension). This evidence concerns the gene AVP and heart failure.